BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 16417444)

  • 21. Two-dose daclizumab, tacrolimus, mycophenolate mofetil, and steroid-free regimen in de novo cardiac transplant recipients: early experience.
    Mastrobuoni S; Ubilla M; Cordero A; Herreros J; Rabago G
    Transplant Proc; 2007 Sep; 39(7):2163-6. PubMed ID: 17889125
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant.
    Pascual J; van Hooff JP; Salmela K; Lang P; Rigotti P; Budde K
    Transplantation; 2006 Jul; 82(1):55-61. PubMed ID: 16861942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tacrolimus combined with mycophenolate mofetil can effectively reverse C4d-positive steroid-resistant acute rejection in Chinese renal allograft recipients.
    Sun Q; Liu ZH; Yin G; Chen H; Chen J; Ji S; Li LS
    Nephrol Dial Transplant; 2006 Feb; 21(2):510-7. PubMed ID: 16421166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discontinuation of mycophenolate mofetil from a tacrolimus-based triple regimen 2 months after renal transplantation: a comparative randomized, multicentre study.
    Sułowicz W; Bachleda P; Rydzewski A; Rutkowski B; Szakály P; Asztalos L; Samlik J; Lacková E; Ksiazek A; Studenik P; Myśliwiec M; Hruby Z; Navrátil P; Gumprecht J
    Transpl Int; 2007 Mar; 20(3):230-7. PubMed ID: 17291216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term results of mycophenolate mofetil as part of immunosuppressive induction therapy after liver transplantation.
    Langrehr JM; Klupp J; Glanemann M; Junge G; Pfitzmann R; Bahra M; Radtke C; Neumann U; Neuhaus R; Neuhaus P
    Clin Transplant; 2006; 20(3):272-83. PubMed ID: 16824141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized long-term trial of tacrolimus and sirolimus versus tacrolimus and mycophenolate mofetil versus cyclosporine (NEORAL) and sirolimus in renal transplantation. I. Drug interactions and rejection at one year.
    Ciancio G; Burke GW; Gaynor JJ; Mattiazzi A; Roth D; Kupin W; Nicolas M; Ruiz P; Rosen A; Miller J
    Transplantation; 2004 Jan; 77(2):244-51. PubMed ID: 14742989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
    Bunnapradist S; Daswani A; Takemoto SK
    Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
    Fisher RA; Stone JJ; Wolfe LG; Rodgers CM; Anderson ML; Sterling RK; Shiffman ML; Luketic VA; Contos MJ; Mills AS; Ferreira-Gonzalez A; Posner MP
    Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Freedom from rejection and stable kidney function are excellent criteria for steroid withdrawal in tacrolimus-treated kidney transplant recipients.
    Włodarczyk Z; Wałaszewski J; Perner F; Vitko S; Ostrowski M; Bachleda P; Kokot F; Klinger M; Szenohradsky P; Studenik P; Navratil P; Asztalos L; Rutkowski B; Nagy KK; Hickey D
    Ann Transplant; 2002; 7(3):28-31. PubMed ID: 12465429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring.
    Meiser BM; Pfeiffer M; Schmidt D; Reichenspurner H; Ueberfuhr P; Paulus D; von Scheidt W; Kreuzer E; Seidel D; Reichart B
    J Heart Lung Transplant; 1999 Feb; 18(2):143-9. PubMed ID: 10194038
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Steroid-free Liver Transplantation Using Rabbit Antithymocyte Globulin Induction in 500 Consecutive Patients.
    Yoo MC; Vanatta JM; Modanlou KA; Campos L; Nezakatgoo N; Nair S; Eason JD
    Transplantation; 2015 Jun; 99(6):1231-5. PubMed ID: 25539464
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of reduced dose of mycophenolate mofetil combined with tacrolimus in living-donor liver transplantation.
    Kim H; Yi NJ; Lee J; Kim J; Moon MR; Jeong J; Lee JM; You TS; Suh SW; Park MS; Choi Y; Hong G; Lee HW; Lee KW; Suh KS
    Clin Mol Hepatol; 2014 Sep; 20(3):291-9. PubMed ID: 25320733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.
    Budde K; Glander P; Krämer BK; Fischer W; Hoffmann U; Bauer S; Grohmann J; Neumayer HH; Arns W
    Transplantation; 2007 Feb; 83(4):417-24. PubMed ID: 17318074
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group.
    Transplantation; 1996 Apr; 61(7):1029-37. PubMed ID: 8623181
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months.
    Gonwa T; Mendez R; Yang HC; Weinstein S; Jensik S; Steinberg S;
    Transplantation; 2003 Apr; 75(8):1213-20. PubMed ID: 12717205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of tacrolimus plus mycophenolate mofetil regimens on acute rejection rate and diabetes mellitus development in renal transplant recipients.
    Demirbaş A; Tuncer M; Yavuz A; Gürkan A; Kaçar S; Cetinkaya R; Tekin S; Akbaş SH; Akaydin M; Ersoy F; Yakupoğlu G
    Transplant Proc; 2004; 36(1):175-7. PubMed ID: 15013338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of early mixed cellular and humoral renal allograft rejection with tacrolimus and mycophenolate mofetil.
    Sun Q; Liu ZH; Cheng Z; Chen J; Ji S; Zeng C; Li LS
    Kidney Int; 2007 Jan; 71(1):24-30. PubMed ID: 16969384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM; Gil-Vernet S; Cruzado JM; Caldés A; Riera L; Serón D; Rama I; Torras J
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Portal donor-specific blood transfusion and mycophenolate mofetil allow steroid avoidance and tacrolimus dose reduction with sustained levels of chimerism in a pig model of intestinal transplantation.
    Gruessner RW; Levay-Young BK; Nakhleh RE; Shearer JD; Dunning M; Nelson CM; Gruessner AC
    Transplantation; 2004 May; 77(10):1500-6. PubMed ID: 15239611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Trough Concentration and Effects of Mycophenolate Mofetil Based on Pathologic Findings in Infants After Liver Transplantation.
    Ueno T; Kodama T; Noguchi Y; Deguchi K; Nomura M; Saka R; Watanabe M; Tazuke Y; Bessho K; Okuyama H
    Transplant Proc; 2020; 52(6):1855-1857. PubMed ID: 32571709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.